A Stanford University study has secured approval to conduct human tests for a cancer vaccine that had a 97% success rate in tests on mice. The vaccine had cured 87 of the 90 mice and the rest were cured after a second treatment. The experiment used two immune-stimulating agents to boost cancer-fighting T-cells, which gets suppressed in cancer patients.